Former President Donald Trump’s victory over Democratic Vice President Kamala Harris in Tuesday’s presidential election capped a series of high-profile [...] …
Category: Federal
The U.S. Supreme Court heard arguments Tuesday on a case challenging a federal rule over disproportionate share hospital (DSH) calculations [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
When voters across the U.S. cast their ballots in Tuesday’s elections, they will not just be deciding who will control [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Eli Lilly announced that it will refund 340B covered entities that purchased certain medications following adjustments to their ceiling prices. [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
The Biden Administration has asked a federal appeals court to reconsider a Texas judge’s ruling that voided a Department of [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Drugmakers Xellia Pharmaceuticals and Ascend Laboratories will refund 340B providers for some products following ceiling price recalculations, according to notices [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
A high-profile former Vermont governor with reported drug industry ties took aim at hospitals’ use of 340B savings, calling for [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
A New Jersey-based drugmaker announced this week that beginning in December, its 340B contract pharmacy restrictions will apply to Health [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
An organization that describes itself as being “comprised of dozens of national, public health, patient advocacy and multicultural organizations,” but [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
The 340B drug discount program continued to be a hot topic for lobbyists in the third quarter of 2024, keeping [...] …